New strategies in bladder cancer

A second coming for immunotherapy

Ali Ghasemzadeh, Trinity Bivalacqua, Noah Hahn, Charles G. Drake

Research output: Contribution to journalArticle

Abstract

Urothelial bladder cancer (UBC) remains one of the most common and deadly cancers worldwide, and platinumbased chemotherapy, which has been the standard-ofcare in metastatic bladder cancer, has had limited success in improving outcomes for patients. The recent development and translation of therapeutic strategies aimed at harnessing the immune system have led to durable and prolonged survival for patients with several different cancers, including UBC. In this review, we discuss new findings in bladder cancer immunotherapy, including recent successes with immune checkpoint blockade. We also discuss therapeutic cancer vaccines and highlight several additional immunotherapy modalities in early stages of development.

Original languageEnglish (US)
Pages (from-to)793-801
Number of pages9
JournalClinical Cancer Research
Volume22
Issue number4
DOIs
StatePublished - Feb 15 2016

Fingerprint

Urinary Bladder Neoplasms
Immunotherapy
Cancer Vaccines
Immune System
Neoplasms
Drug Therapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

New strategies in bladder cancer : A second coming for immunotherapy. / Ghasemzadeh, Ali; Bivalacqua, Trinity; Hahn, Noah; Drake, Charles G.

In: Clinical Cancer Research, Vol. 22, No. 4, 15.02.2016, p. 793-801.

Research output: Contribution to journalArticle

@article{3a164a800e754bb79360bb6dc9ac69cb,
title = "New strategies in bladder cancer: A second coming for immunotherapy",
abstract = "Urothelial bladder cancer (UBC) remains one of the most common and deadly cancers worldwide, and platinumbased chemotherapy, which has been the standard-ofcare in metastatic bladder cancer, has had limited success in improving outcomes for patients. The recent development and translation of therapeutic strategies aimed at harnessing the immune system have led to durable and prolonged survival for patients with several different cancers, including UBC. In this review, we discuss new findings in bladder cancer immunotherapy, including recent successes with immune checkpoint blockade. We also discuss therapeutic cancer vaccines and highlight several additional immunotherapy modalities in early stages of development.",
author = "Ali Ghasemzadeh and Trinity Bivalacqua and Noah Hahn and Drake, {Charles G.}",
year = "2016",
month = "2",
day = "15",
doi = "10.1158/1078-0432.CCR-15-1135",
language = "English (US)",
volume = "22",
pages = "793--801",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - New strategies in bladder cancer

T2 - A second coming for immunotherapy

AU - Ghasemzadeh, Ali

AU - Bivalacqua, Trinity

AU - Hahn, Noah

AU - Drake, Charles G.

PY - 2016/2/15

Y1 - 2016/2/15

N2 - Urothelial bladder cancer (UBC) remains one of the most common and deadly cancers worldwide, and platinumbased chemotherapy, which has been the standard-ofcare in metastatic bladder cancer, has had limited success in improving outcomes for patients. The recent development and translation of therapeutic strategies aimed at harnessing the immune system have led to durable and prolonged survival for patients with several different cancers, including UBC. In this review, we discuss new findings in bladder cancer immunotherapy, including recent successes with immune checkpoint blockade. We also discuss therapeutic cancer vaccines and highlight several additional immunotherapy modalities in early stages of development.

AB - Urothelial bladder cancer (UBC) remains one of the most common and deadly cancers worldwide, and platinumbased chemotherapy, which has been the standard-ofcare in metastatic bladder cancer, has had limited success in improving outcomes for patients. The recent development and translation of therapeutic strategies aimed at harnessing the immune system have led to durable and prolonged survival for patients with several different cancers, including UBC. In this review, we discuss new findings in bladder cancer immunotherapy, including recent successes with immune checkpoint blockade. We also discuss therapeutic cancer vaccines and highlight several additional immunotherapy modalities in early stages of development.

UR - http://www.scopus.com/inward/record.url?scp=84964322531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964322531&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-1135

DO - 10.1158/1078-0432.CCR-15-1135

M3 - Article

VL - 22

SP - 793

EP - 801

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -